Table 6.
Antimicrobial resistance rates according to qacEΔ1-sul1 status.
| Antimicrobial | qacEΔ1-sul1-positive (n=29), resistant n (%) | qacEΔ1-sul1-negative (n=51), resistant n (%) | Test statistic | Unadjusted P | q value (BH-FDR) | Holm-adjusted P |
| Cefepime (FEP) | 7 (24.10) | 10 (19.60) | χ² = 0.238 | 0.626 | 0.805 | 1.000 |
| Ceftazidime (CAZ) | 10 (34.50) | 10 (19.60) | χ² = 2.035 | 0.154 | 0.346 | 0.838 |
| Amikacin (AMK) | 6 (20.70) | 4 (7.80) | Fisher | 0.101 | 0.303 | 0.664 |
| Aztreonam (ATM) | 16 (55.20) | 14 (27.50) | χ² = 5.782 | 0.016 | 0.072 | 0.111 |
| Piperacillin/tazobactam (TZP) | 11 (37.90) | 13 (25.50) | χ² = 1.319 | 0.251 | 0.450 | 1.000 |
| Tobramycin (TOB) | 4 (13.80) | 5 (9.80) | Fisher | 0.718 | 0.808 | 1.000 |
| Levofloxacin (LVX) | 8 (27.60) | 13 (25.50) | χ² = 0.042 | 0.837 | 0.837 | 1.000 |
| Meropenem (MEM) | 25 (86.20) | 30 (58.80) | χ² = 6.416 | 0.011 | 0.072 | 0.100 |
| Imipenem (IPM) | 26 (89.70) | 41 (80.40) | χ² = 1.075 | 0.300 | 0.450 | 1.000 |
Fisher’s exact test was used for amikacin and tobramycin because expected cell frequencies fell below five; the χ² test was used otherwise. q values were calculated by the Benjamini–Hochberg false discovery rate procedure across all nine comparisons in this exploratory family. Holm-adjusted P values are reported as a sensitivity analysis. After correction by either procedure, no association retained statistical significance. BH-FDR, Benjamini–Hochberg false discovery rate.